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 [1] . The host’s initial defense mechanisms against GAS 
involve the physical barriers of mucosa or skin and their 
commensal microflora. Once GAS has breached the epi-
thelium, eradication by soluble factors and phagocytes 
is required, and quick and accurate recognition of GAS 
by the host innate immune system can prevent disease 
spread. Pattern recognition receptors such as Toll-like re-
ceptors (TLRs) recognize conserved molecular patterns 
from pathogens; most TLRs will initiate signal transduc-
tion via the central adaptor protein myeloid differentia-
tion factor 88 (MyD88). MyD88 has recently been shown 
to play an important role in innate defense against GAS 
infection  [2] .
 Though classically described as an extracellular patho-
gen, studies have shown that GAS may survive intracel-
lularly for several hours within epithelial cells  [3–5] , mac-
rophages  [6, 7] and neutrophils  [8, 9] . These data led us to 
hypothesize that the intracellularly localized TLR9 could 
be important for GAS detection and elimination. TLR9 
is found in endosomes and is stimulated by nonmethyl-
ated DNA and synthetic CpG oligodeoxynucleotides  [10, 
11] or during infection with obligate intracellular bacteria 
including  Listeria monocytogenes and  Legionella pneu-
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 Abstract 
 Timely recognition and elimination of invasive group A 
 Streptococcus (GAS) by innate immunity is crucial to control 
infection. The intracellular pattern recognition receptor Toll-
like receptor 9 (TLR9) promotes macrophage hypoxia-induc-
ible factor-1  levels, oxidative burst and nitric oxide produc-
tion in response to GAS. TLR9 contributes to GAS clearance 
in vivo in both localized cutaneous and systemic infection 
models. 
 
Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 The Gram-positive bacterium group A  Streptococcus 
 (GAS) is a leading human pathogen causing  1 700 million 
superficial infections such as pharyngitis or pyoderma 
and  1 650,000 invasive infections worldwide every year 
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mophila  [12, 13] . To date, the role of TLR9 in innate de-
fense against bacteria that exist mainly extracellulary has 
not been fully elucidated  [14, 15] and remains controver-
sial  [16–19] .
 Methods 
 Mice and Bacterial Strains 
 C57BL/6 wild-type (WT) and TLR9-deficient mice in the 
C57BL/6 background were used in this study. TLR9-deficient 
mice were a gift from Dr. Shizuo Akira (Osaka University, Japan) 
and were bred and handled in our facilities under the approved 
protocols of the University of California San Diego Animal Care 
Committee. WT mice were purchased from Charles River.
 GAS M1T1 strain 5448 was originally isolated from a patient 
with necrotizing fasciitis and toxic shock syndrome  [20] . GAS 
were propagated in Todd-Hewitt broth (Difco, BD Diagnostics) 
or Todd-Hewitt agar plates. In macrophage and mouse challenge 
studies, bacteria were grown to logarithmic phase in Todd-
Hewitt broth [optical density at 600 nm = 0.4 = approx. 2  ! 10 8 
colony-forming units (CFU)/ml], pelleted, washed and resus-
pended in PBS or in tissue culture media at the desired concen-
tration.
 Macrophage Killing Assays 
 Peritoneal macrophages were isolated from the peritoneal cav-
ity of WT and TLR9-deficient mice 72 h after injection of thiogly-
collate, as previously described  [21] . Harvested macrophages were 
washed and resuspended in RPMI-1640 containing 10% heat-in-
activated fetal bovine serum (FBS). In a 48-well plate, 10 6 macro-
phages were added per well and incubated for 24 h at 37   °   C with 
5% CO 2 . Then cells were washed twice and resuspended in RPMI-
1640 containing 2% FBS. Where indicated, the TLR9 antagonist 
guanosine-rich inhibitory oligonucleotide (G-ODN; 5   M ; Invi-
vogen, Carlsbad, Calif., USA) was added. After 1 h, logarithmic 
phase bacteria were added to the wells at a final multiplicity of 
infection (MOI) of 0.1–0.2 and centrifuged for 5 min at 1,500 rpm. 
After 4 h of incubation at 37   °   C with 5% CO 2 , macrophages were 
detached with trypsin and lysed with 0.025% Triton X in PBS for 
serial dilutions to enumerate surviving bacteria (plated on Todd-
Hewitt agar). 
 Oxidative Burst and Nitric Oxide Expression 
 For reactive oxygen species (ROS) determination, bone mar-
row (BM)-derived macrophages were used. The BM cells of fe-
murs and tibias of WT and TLR9-deficient mice were collected. 
Cells were plated in Dulbecco’s modified Eagle medium supple-
mented with 10% heat-inactivated FBS and 30% conditioned 
medium as described elsewhere  [22] . Mature adherent BM-de-
rived macrophages were harvested by gentle scraping after 7 
days in culture and reseeded for the assay. On day 10, macro-
phages were washed twice, resuspended in Hanks’ balanced salt 
solution and incubated with 30   M 2,7-dichlorofluorescein di-
acetate for 30 min of rotation at 37  °  C. Cells were washed 3 times 
with PBS and resuspended in Hanks’ balanced salt solution for 
a final concentration of 5  ! 10 5 in 100   l of solution per well of 
a 96-well plate. Where indicated, logarithmic phase bacteria 
were added at an MOI of 1: 1. After 270 min, the fluorescence 
signal was measured with excitation at 485 nm and emission at 
535 nm using a f luorescent plate reader (Wallac II, Perkin El-
mer). Nitric oxide (NO) expression was determined by the Griess 
reaction in peritoneal macrophages as previously described  [23] ; 
baseline values (no GAS stimulation) were subtracted from in-
dicated values. 
 Hypoxia-Inducible Factor-1  Detection by Western Blot and 
Immunostaining 
 BM-derived macrophages were harvested and cultured as de-
scribed above. After 7 days in culture, mature macrophages were 
reseeded into 100-mm 2 wells for Western blot analysis or onto 12-
mm 2 glass cover slides in 24-well plates for immunostaining. 
Macrophages were then either challenged with WT GAS (MOI 10) 
or were not exposed to bacteria. After 1 h of incubation, penicillin 
and gentamicin (10 and 100   g/ml, respectively) were added to all 
the wells and macrophages were incubated for an additional 3 h. 
For Western blot analysis, cells were harvested and washed (in 
PBS), and proteins were extracted with RIPA buffer. Nuclear ex-
tracts (20   g) were loaded onto a 12% Tris-tricine gel in a 2-( N -
morpholino)ethanesulfonic acid buffer (Invitrogen) for hypoxia-
inducible factor (HIF)-1  Western blot using standard method-
ologies  [24] . For immunostaining, cells were immediately fixed 
with 4% paraformaldehyde and kept at 4  °  C until further analysis. 
After washing, cells were perme abilized for 45 min with PBS con-
taining 2% BSA, 0.2% Triton X-100 and 5% goat serum.
 After additional washes, rabbit anti-HIF-1  (Novus Biologi-
cals; diluted 1: 100 in PBS-Tween) was added for 60 min at room 
temperature followed by Alexa Fluor 488-conjugated goat anti-
rabbit IgG (green; Invitrogen; diluted 1: 500 in PBS-Tween) for 
45 min at room temperature. After washing, samples were em-
bedded in Prolong Gold antifade containing DAPI for counter-
staining (blue; Invitrogen). Mounted samples were examined 
using an inverted confocal laser scanning 2-photon microscope 
(Olympus Fluoview FV1000, Olympus  ! 20/0.7 UPlanSApo ob-
jective) with Fluoview TM Spectral Scanning technology (Olym-
pus America, Center Valley, Pa., USA) or, alternatively, using a 
Zeiss Axiolab microscope (Zeiss  ! 20/0.5 Plan-Neofluor objec-
tive; Carl Zeiss, San Diego, Calif., USA) with an attached Sony 
Digital Photo Camera DKC-5000 (Sony, USA) at calibrated mag-
nifications. Mean fluorescence intensities as markers for HIF-1  
expression levels were measured at equal exposure times and 
quantified using Image J (National Institutes of Health, Bethes-
da, Md., USA). HIF-1  levels were calculated by dividing the 
HIF-1  -specific signal by the background subtracted DAPI-re-
lated signal. 
 Mouse Infection Models 
 Logarithmic phase GAS were resuspended in PBS and mixed 
1: 1 with sterile Cytodex beads (Sigma, St. Louis, Mo., USA), and 
an inoculum of 5  ! 10 7 CFU of GAS was injected subcutane-
ously into one flank of 10- to 12-week-old WT or TLR9-deficient 
mice (total injected volume per mouse 100   l). The size of devel-
oping necrotic lesions was monitored daily for 4 days, at which 
time mice were euthanized and skin lesions were harvested for 
bacterial counts. In systemic challenge experiments, 12-week-old 
mice (WT and TLR9-deficient) were given intraperitoneal injec-
tions of mid-log phase GAS (5  ! 10 7 CFU) in 500   l of PBS or 
PBS alone as a control. After 24 h, blood was collected for bacte-
rial counts. 
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 Statistics 
 For comparisons of two groups of either paired or unpaired 
samples we used the nonparametric Wilcoxon test or t test, and 
for 3-sample comparison we used nonparametric Kruskal-Wallis 
one-way ANOVA on ranks. If the ANOVA analysis was signifi-
cant, Bonferroni pair-wise group comparison was performed. 
The log rank test was used for survival analysis. p values were cal-
culated using the software packages NCSS 2007 (NCSS, Kaysville, 
Utah, USA) and SPSS Statistics 17.0 (SPSS, Chicago, Ill., USA). 
 Results and Discussion 
 To directly test the importance of TLR9 for the recog-
nition and clearance of GAS in vivo, we challenged WT 
and TLR9-deficient mice with the invasive M1T1 GAS 
strain 5448 using a previously described model of necro-
tizing subcutaneous infection  [25] and monitored the de-
velopment of lesions over 4 days. TLR9-deficient mice de-
veloped significantly larger necrotizing skin lesions than 
did WT mice ( fig. 1 a, b). Mice were sacrificed on day 4, 
and the bacterial load in the excised skin lesions of TLR9-
deficient mice was significantly higher than that in WT 
controls ( fig. 1 c).
 GAS can cause bacteremic infections and toxic shock 
syndrome with high morbidity and mortality. To test the 
importance of TLR9 in a systemic infection model, WT 
and TLR9-deficient mice were injected intraperitoneally 
with logarithmic phase M1T1 GAS, and blood was col-
lected at 24 h for enumeration of CFUs. TLR9-deficient 
mice resolved GAS bacteremia less effectively than did 
WT mice ( fig. 1 d), and the impaired GAS clearance ob-
served in TLR9-deficient mice was reflected in increased 
mortality ( fig. 1 e). Altogether, these animal data show 
for the first time that TLR9 is important for controlling 
GAS in vivo during localized cutaneous or systemic in-
fection. 
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 Fig. 1. TLR9 is important for controlling GAS infection in vivo.
 a C57BL/6 (WT) and TLR9-deficient mice were injected subcu-
taneously with equivalent inocula of the M1 GAS strain, and
skin lesion progression was measured for 4 days.  b Representa-
tive photograph of skin lesions seen in the subcutaneous chal-
lenge experiment.  c After 4 days, there were twice as many bac-
teria in the skin in the TLR9-deficient mice compared to the WT 
mice.  d Using an intraperitoneal infection model, a subset of the 
mice (5 WT and 4 TLR9-deficient mice) were bled 24 h after GAS 
infection, and bacteremia was evaluated by serial dilution of the 
blood.  e Survival of WT (n = 13) and TLR9-deficient (n = 12) mice 
followed over 1 week after intraperitoneal infection. Data are pre-
sented as means  8 SEM. TLR9KO = TLR9-deficient. 
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 Fig. 2. TLR9 mediates killing of GAS by macrophages.  a Surviv-
ing GAS after incubation with WT macrophages or TLR9-defi-
cient macrophages at an MOI of 1, with and without the TLR9 
antagonist G-ODN.  b ,  c WT and TLR9-deficient macrophages 
were incubated with GAS at an MOI of 1, and ROS ( b ) and NO ( c ) 
was quantified. Data are given as box plots with n = 6 per point 
and 3 repeats ( a ) or as means  8 SEM with n = 6 ( b ) and n = 3 ( c ) 
(representative experiment from 3 independent experiments). 
ANOVA was significant at p = 0.01, with Bonferroni pair-wise 
group comparison at  *   p  ! 0.05 and  * *   p  ! 0.005. TLR9KO = 
TLR9-deficient; OD = optical density at 540 nm. 
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 Fig. 3. TLR9 promotes HIF-1  expression. 
WT and TLR9-deficient macrophages 
were challenged with GAS.  a Represen-
tative immunofluorescence micrograph.
 b Quantification of HIF-1  expression 
(infected cells, n = 14, images of 3 indepen-
dent experiments; noninfected cells, n = 8, 
images of 2 independent experiments).
 c Nuclear extracts of the same cells were 
analyzed for HIF-1  expression by West-
ern blot with analysis of   -actin as a load-
ing control. Data are presented as means 
 8 SEM. Scale bars = 100   m. TLR9KO = 
TLR9-deficient; n.s. = not significant. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
22
/2
01
6 
5:
03
:3
1 
PM
 TLR9 and Group A  Streptococcus J Innate Immun 2012;4:213–218 217
WT mouse macrophages. The residual HIF-1  induction 
still detectable in the TLR9-deficient mouse macrophages 
after GAS challenge could be due to the redundant effects 
of other pattern recognition receptors such as TLR2, 
TLR4 and TLR6, which contribute to HIF-1  induction 
and stabilization  [31, 32] , likely through NF-  B-depen-
dent increases in HIF-1  transcript  [33] . Also, GAS has 
been shown to be able to induce multiple inflammatory 
responses via MyD88-dependent TLR2/TLR4/TLR9-in-
dependent signaling  [19] , as has been shown for other 
Gram-positive pathogens  [16, 34] .
 In summary, this study shows that TLR9 plays an im-
portant role in host defense against GAS infections and 
that stimulation of TLR9 improves macrophage killing of 
this leading human pathogen. TLR9-induced stabiliza-
tion of the transcription factor HIF-1  and increased 
generation of bactericidal ROS and NO are likely contrib-
uting factors to the observed innate immune phenotypes.
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 Macrophages, which express TLR9  [26] , play a key role 
in the defense against GAS infections  [27, 28] . We hy-
pothesized that the impaired clearance of GAS in TLR9-
deficient animals could be explained by inefficient killing 
of GAS by macrophages lacking TLR9 signaling. We thus 
studied the contribution of TLR9 to GAS clearance using 
in vitro killing assays and genetically or pharmacologi-
cally modified murine macrophages. GAS was killed ef-
ficiently when incubated with WT macrophages; how-
ever, killing was significantly impaired if TLR9 was ab-
sent or pharmacologically blocked by the TLR9 antago-
nist G-ODN ( fig. 2 a).
 Macrophages kill GAS efficiently in part through pro-
duction of ROS and NO  [28] . Macrophages from WT and 
TLR9-deficient mice were incubated with GAS, and ROS 
and NO production was quantitated after 30 min. TLR9-
deficient macrophages produced significantly less ROS 
( fig. 2 b) and NO ( fig. 2 c) in response to GAS than did WT 
macrophages. These results suggest that impaired control 
of GAS infection in TLR9-deficient mice may in part be 
related to diminished NO- and ROS-mediated macro-
phage killing.
 HIF-1  is a key transcriptional regulator orchestrating 
myeloid cell inflammatory and innate immune responses 
 [29] . GAS infection leads to increased levels of HIF-1  in 
macrophages  [23] , and HIF-1  is important for regulat-
ing macrophage production of ROS and NO in response 
to infection  [23, 30] . We challenged WT and TLR9-defi-
cient macrophages with GAS and determined the intra-
nuclear content of HIF-1  by immunostaining ( fig. 3 a, b; 
online suppl. fig.  1; for all online suppl. material, see 
www.karger.com/doi/10.1159/000329550) and Western 
blotting ( fig. 3 c). After GAS challenge, HIF-1  stabiliza-
tion was less pronounced in TLR9-deficient compared to 
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